Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Prostate Cancer
Interventions: DRUG: VT-464: given orally twice daily in 28-day cycles|DRUG: VT-464: given orally once daily in 28-day cycles
Sponsor: Innocrin Pharmaceutical
Collaborators: National Cancer Institute (NCI)